Pulmonary Hypertension: Dissecting a Complex Phenotype.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Exploring the Toxicological Impacts of DOTP Exposure on Pulmonary Arterial Hypertension via Network Toxicology, Virtual Knockout, Molecular Docking and Experimental Validation.International journal of molecular sciences · 2026
   Article
2. New insights into pulmonary arterial hypertension: interaction between PANoptosis and perivascular inflammatory responses.Apoptosis : an international journal on programmed cell death · 2025
   Review
3. Chest Computed Tomography to Improve Phenotyping in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2025
   Article

Corrections and comments

• Comment on
  Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as